Nemysis

Executive Summary

Nemysis is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2016 by industry experts with a proven track record in healthcare product delivery. The company focuses on addressing worldwide nutritional deficiencies while preserving the patient's microbiome, thereby minimizing gastrointestinal side effects. With a portfolio targeting conditions such as iron, vitamin D, and B12 deficiencies, Nemysis differentiates itself through formulations designed to avoid microbiome disruption—a common cause of GI intolerance in standard supplements. The company operates in the diagnostics and infectious disease categories, indicating potential expansion into diagnostic tools for deficiency detection or infection-linked nutritional issues. As a private entity with no disclosed funding or valuation, Nemysis remains early-stage but leverages its founders' experience to navigate regulatory pathways and commercialization. The growing awareness of gut health and the microbiome's role in overall wellness positions Nemysis to capture demand in both developed and emerging markets, where nutrient deficiencies are prevalent and patients seek better-tolerated therapies.

Upcoming Catalysts (preview)

• Q3 2026Launch of microbiome-friendly iron supplement in European market65% success
• Q4 2026Partnership with global pharmaceutical distributor for Latin American expansion50% success
• Q2 2026Publication of clinical data showing improved GI tolerability vs. standard vitamin D formulations75% success